O B J E C T I V E -To determine whether American Diabetes Association (ADA) guidelines can be met in the context of routine endocrinology practice.
S
t rong evidence exists that good diabetes management results in significant benefits. In 1993, the Diabetes C o n t rol and Complications Trial (DCCT) showed that intensive insulin tre a t m e n t significantly reduced the development and p ro g ression of microvascular complications in patients with type 1 diabetes (1). Both the Kumamoto Study (2) and the U.K. P rospective Diabetes Study (UKPDS) (3) showed that intensive therapy re d u c e d m i c rovascular complications in patients with type 2 diabetes as well. Evidence also exists that aggressively managing card i ovascular risk factors in patients with diabetes is beneficial. A subgroup analysis of the Scandinavian Simvastatin Surv i v a l Study (4) showed that patients with diabetes who took simvastatin had a significant reduction in major coro n a ry heart disease events, and the UKPDS found that tight blood pre s s u re (BP) control in patients with type 2 diabetes reduced the risk of s t roke, microvascular disease, and deaths related to diabetes (5).
Despite such re i n f o rcement for aggre ssive management, many patients continue to receive suboptimal care. Although the American Diabetes Association (ADA) guidelines for desired HbA 1 c values, lipid and BP goals, and screening pro c e d u res have been widely distributed, these goals often are not met in the primary care settings where most patients receive their diabetes care (6-10). However, few studies have focused on specialist practice, and whether specialists are able to meet ADA guidelines is not c l e a r. In 1995, the Medical Outcomes Study (11) found no "meaningful diff e rences" in health outcomes (including glycemic cont rol) in patients with diabetes who were t reated by specialists or generalists. On the other hand, the DCCT showed that specialists could achieve good results in diabetes management in a study setting at a substantial cost (12). In short, limited evidence shows that diabetes specialists can meet ADA guidelines in routine practice. To determine whether DCCT-level glycemic contro l and adequate screening can be attained in this context, we assessed the quality of care for patients with diabetes managed by academic endocrinologists at the Emory Clinic. level of education. Of the patients at the E m o ry Clinic, 36% receive Medicare benefits, and 4% receive Medicaid. The Diabetes Unit at the time of this study was staff e d primarily by two endocrinologists, two nurse practitioners, and a re g i s t e red dietitian. Other endocrinologists examined 15% of patients in the Diabetes Unit during the study period. Although the Emory Clinic is an academic setting, the physicians involved are expected to support their salaries with patient care eff o rts. This usually results in a physician examining 12-18 patients during each half day at the clinic.
Management overview
Although no set protocol exists, patients with type 2 diabetes are generally managed with individualized pro g ressive intensification of therapy. Diet and exercise are encouraged with oral hypoglycemic agents as the initial pharmacological therapy. If patients exhibit poor glycemic contro l despite combinations of oral hypoglycemic agents, then insulin is frequently start e d with NPH insulin at bedtime. Finally, two or more daily insulin injections are used as needed to maintain tight glycemic contro l .
Physicians see patients in conjunction with nurse practitioners; visits with both physicians and nurse practitioners generally alternate with visits with nurse practitioners alone. Patients also have dire c t telephone access to nurse practitioners should patients have problems. The extensive use of physician extenders allows more f requent contact with patients and adjustment of therapy between office visits. Data f rom each visit are re c o rded on a flow sheet that stays with the patient' s chart to allow easy review of laboratory data, scre e n i n g tests, and medications. No formal system is in place to remind providers when scre e ning tests are due.
Patients
By using the physicians' schedule data, c h a rts were reviewed beginning with patients who had been seen most re c e n t l y in December 1998. Working back thro u g h 1998, charts were examined until 1 2 0 patients who met the inclusion criteria for type 2 diabetes were found. Assignment to the type 2 diabetes group was based on clinical criteria such as onset of diabetes at an age 30 years, current or prior use of noninsulin diabetes therapy, obesity, and lack of a history of diabetic ketoacidosis. Patients were included if they had seen the same endocrinologist (L.S.P. or S.S.P.G.) for at least 1 year (to allow time for clinical practices to take effect) and had at least two visits during that year (to exclude patients who had only a single visit). Although the focus of the study was patients with type 2 diabetes, those patients encountered during c h a rt review who had type 1 diabetes were included in a separate analysis.
Main data outcomes P r i m a ry data for patients with type 2 diabetes included the most recent HbA 1 c , random plasma glucose, and lipid pro f i l e s ; whether patients had a dilated eye examination by an eye specialist, a urine albumin assessment, or a lipid profile within the last year; and whether patients had a foot examination re c o rded at their most recent visit. Treatment regimens were also assessed. In addition, rates of peripheral neuro p a t h y, albuminuria, re t i n o p a t h y, hypert e n s i o n , hyperlipidemia, coro n a ry art e ry disease, and peripheral vascular disease for the population were determined. Because of the small number of patients with type 1 diabetes, analysis of their data was limited to H b A 1 c values and insulin regimens. Data w e re collected primarily from the flow sheet, but when these sheets were incomplete, office notes were examined. Finally, when demographic information could not be obtained from the chart (e.g., date of onset of diabetes), the patient was contacted d i rectly by telephone. Telephone contact was necessary for 15% of patients.
Identifying complications
Most complications could be assessed fro m the flow sheet or from the most re c e n t clinic note. Patients were classified as having a complication if it was included in the p roblem list in previous notes or if other criteria were met, including the following. First, peripheral neuropathy was diagnosed if vibratory sense at the distal end of the first metatarsal was 15 s or if the patient failed the standard 10-g filament test. Second, albuminuria was diagnosed if albumin excretion was 30 mg/24 h or if a spot urine albumin/creatinine ratio was 0.030 mg/mg. Third, diagnosis of retinopathy was based on patient selfre p o rts from eye specialist visits or a hist o ry of laser or surgical therapy. Fourt h , h y p e rtension was diagnosed if the patient had been taking antihypertensive medication (other than ACE inhibitors if the patient had albuminuria) or if a recent BP m e a s u rement was 130/85 mmHg. Fifth, c o ro n a ry art e ry disease was diagnosed if p roblems such as angina, congestive heart f a i l u re, or myocardial infarction were included in the problem list. Sixth, hyperlipidemia was diagnosed if the patient was taking lipid-lowering medication, if a recent LDL cholesterol measurement was 3.36 mmol/l (130 mg/dl), or if a re c e n t triglyceride level was 2.26 mmol/l (200 mg/dl) (per ADA guidelines that were operative in 1998) (13). Finally, peripheral vascular disease was diagnosed if the clinic notes documented diminished peripheral pulses, carotid bruits, or carotid or lowere x t remity vascular surg e ry or if the patient had a history of nontraumatic amputation without evidence of peripheral neuro p a t h y. 
Statistical analysis
Statistical analysis was carried out with Statview 5.0 (SAS Institute, Cary, NC). Analysis of variance and unpaired twot a i l e d t tests were used to compare means between subgroups of patients. P v a l u e s 0.05 were considered to be significant.
R E S U LT S

Demographics
A total of 151 patients were included in the s t u d y, and 80% had type 2 diabetes. Patients with type 2 diabetes were 53% men, were 26% African-American, had an average age of 63 years, had an average duration of diabetes of 12 years, and had an average BMI of 31 kg/m 2 . The median number of visits was 4 (range 2-14) within the 12 months surveyed. For patients with type 1 diabetes, the average age was 44 years, the average duration of diabetes was 20 years, and the average BMI was 26 k g / m 2 . Equal numbers of male and female patients had type 1 diabetes, and they were seen a median of four times (range 2-9).
Meeting ADA guidelines in endocrinologist practice
Diabetes complications
Many patients with type 2 diabetes had complications from their diabetes, and comorbidities were common. A total of 78% had peripheral neuro p a t h y, 22% had re t i n o p a t h y, 21% had albuminuria, 80% had hypertension, 64% had hyperlipidemia, 27% had coro n a ry art e ry disease, and 14% had peripheral vascular disease.
S c reening for diabetes complications
S c reening studies in most patients with type 2 diabetes approached ADA guidelines. The rate of documented foot examinations at the most recent visit was highest at 87% of patients, followed by dilated eye examinations within the past year (74%) and lipid profiles within the past year (70%). Urine albumin screening was perf o rmed least fre q u e n t l y, with measure m e n t s within the past year in 55% of patients.
Metabolic outcomes
Patients with type 2 diabetes had an average BP level of 133/72 mmHg, an average chol e s t e rol level of 4.63 mmol/l (179 mg/dl), an average triglyceride level of 1.99 mmol/l (176 mg/dl), an average HDL cholestero l level of 1.24 mmol/l (48 mg/dl), and an average LDL cholesterol level of 2.61 mmol/l (101 mg/dl). A total of 65% of patients were taking antihypertensive medications; of those, 62% had a BP level of 1 4 0 / 9 0 mmHg, and 41% had a BP level of 1 3 0 / 8 5 mmHg. A total of 55% of patients had been taking lipid-lowering medications. In patients taking lipid-lowering medication, the total cholesterol level averaged 4.55 mmol/l (176 mg/dl), the triglyceride level averaged 2.10 mmol/l (186 mg/dl), the HDL c h o l e s t e rol level averaged 1.24 mmol/l (48 mg/dl), and the LDL cholesterol level averaged 2.48 (96 mg/dl). In patients not taking lipid-lowering medications, the total cholest e rol level averaged 4.78 mmol/l (185 mg/dl), the triglyceride level averaged 1.77 mmol/l (157 mg/dl), the HDL cholestero l level averaged 1.27 mmol/l (49 mg/dl), and the LDL cholesterol level averaged 2.82 mmol/l (109 mg/dl). For patients with type 2 diabetes, the random blood glucose level averaged 8.0 mmol/l (144 ± 6 mg/dl), and the HbA 1 c level averaged 6.9 ± 0.1%. A total of 61% of patients with type 2 diabetes had H b A 1 c levels 7.0%, 87% had HbA 1 c l e v e l s 8.0%, and 4% had HbA 1 c levels 9 % (Fig. 1) . Patients managed with diet therapy alone had significantly lower HbA 1 c v a l u e s (5.7%) than patients managed with a combination of oral hypoglycemic agents and insulin or insulin alone (both groups 7.2%; P 0.05 vs. diet alone). HbA 1 c levels for patients managed only with oral hypoglycemic agents (6.6%) did not differ significantly from the other groups. No diff e re n c e in HbA 1 c level was evident based on sex, race, duration of diabetes, or age (patients aged 65 vs. 65 years).
Management
The management of patients with type 2 diabetes was complex, and nearly all patients re q u i red pharmacological therapy (Fig. 2) . Ve ry few patients (5%) were managed with diet therapy alone. A total of 38% were managed with oral hypoglycemic agents alone, and 54% of these patients used more than one agent. The most common combinations of oral therapy were sulfonylure a / m e t f o rmin (21% of the total patients managed with oral hypoglycemic agents alone) and sulfonylure a / t roglitazone (17%). Of the patients, 57% w e re using insulin (either alone or in combination with oral hypoglycemic agents). Of those using insulin and oral hypoglycemic agents, 46% were taking an insulin sensitizer (metformin or tro g l i t azone). Patients using any insulin averaged 64 U/day (0.68 U k g 1 d a y 1 ), and 4 2 % w e re taking three or more daily inject i o n s . Overall, most patients (78%) re q u i red more than diet or a single oral hypoglycemic agent for adequate contro l .
Type 1 diabetes
All patients with type 1 diabetes were managed with insulin. They averaged 49 U (0.66 U k g 1 d a y 1 ) of insulin and 3.4 injections per day, and 87% were taking t h ree or more daily injections. The mean H b A 1 c level for patients with type 1 diabetes was 7.1 ± 0.2%. A total of 57% of patients with type 1 diabetes had HbA 1 c levels 7.0%, 80% had HbA 1 c l e v e l s 8.0%, and 10% had HbA 1 c levels 9 % (Fig. 1) . Again, no significant diff e re n c e was evident in HbA 1 c levels based on sex, race, duration of diabetes, or age.
C O N C L U S I O N S -
This study provides evidence that ADA guidelines and D C C T-level glycemic control can be achieved in specialist practice. Although comorbidities and diabetes complications w e re frequent, patients with type 2 diabetes had good glycemic control. Complex tre a tment regimens were necessary; only 22% of patients were treated solely with diet therapy or a single oral hypoglycemic agent. Most patients had appro p r i a t e s c reening examinations, and BP and lipid outcomes were also good.
These findings contrast with pre v i o u s studies that were based mostly on patients in primary care settings and that often have shown glycemic control to be re l a t i v e l y p o o r. Martin et al. (6) studied 378 patients with type 2 diabetes in 1992-1993 and found that mean HbA 1 c values ranged fro m 8.6% in whites to 9.4% in blacks and 9.8% in Hispanics. In 1994, Weatherspoon et al. 
Miller and Associates
(7) re p o rted that nearly 40% of patients with type 2 diabetes had HbA 1 c values of 8%. We found no significant diff e rence in H b A 1 c levels based on race, and only 15% of our patients with type 2 diabetes had H b A 1 c levels of 8%. Most re c e n t l y, Harr i s et al. (8) found a mean HbA 1 c level of 7.6% in patients with diabetes in the Third National Health and Nutrition Examination Survey (NHANES III), but patients using only oral hypoglycemic agents (46% of patients) averaged HbA 1 c levels of 8.0%, and patients using any insulin (27% of patients) averaged HbA 1 c levels of 8.3%. In comparison, our group taking oral hypoglycemic agents only had average HbA 1 c levels of 6.6%, and patients using any insulin had average HbA 1 c levels of 7.2%.
I m p roved glycemic control in this study may be attributable to our use of complex therapeutic regimens. Although similar numbers of patients were using oral hypoglycemic agents only (38 vs. 46% in the study by Harris et al. [8] ) and insulin only (26 vs. 24%), substantially fewer of our patients were using diet therapy alone (5 vs. 27%), and substantially more were using oral hypoglycemic agents plus insulin (31 vs. 3%). In addition, more of our insulint reated patients were injecting insulin thre e or more times a day (42 vs. 4%) (8). Although we found that good control could be obtained with insulin dosages averaging only 0.7 U k g 1 d a y 1 , insulin needs w e re likely reduced by the concomitant use of oral hypoglycemic agents.
In addition to metabolic outcomes, p rocess measures are also important in good diabetes care. Screening rates in our patients with type 2 diabetes were generally good, especially for eye examinations and lipid p rofiles, and were somewhat higher than those previously re p o rted for several gro u p s of patients from large claims databases. In two studies of Medicare patients, 40-46% of patients had ophthalmological examinations, and 55-56% had lipid measure m e n t s during a 1-year period (9,10). Martin et al. (6) found that 53-66% of patients had annual ophthalmological examinations, 52-62% had at least one total cholestero l and one HDL cholesterol measurement during a 2-year period, and 56-63% had at least two urine dipstick tests during a 2-year period. Another study re p o rted that 48% of 353 patients with diabetes had urine protein screenings (test not specified), but 92% had no documented foot examinations during a 1-year period (14).
Our data are not the first to suggest that specialists may be able to meet ADA guidelines better than primary care practice physicians. Ho et al. (15) have shown that p rocess measures are addressed better by specialists, and Hellman et al. (16) achieved a median HbA 1 c level of 7.3% in patients who had received long-term care in their specialty practice. However, we believe our study is the first re p o rt to assess patient complexity and details of management in specialist practice.
The discrepancies between our data and those of primary care studies may be because of factors other than the type of t reating physician. First, data used in the studies mentioned above are principally f rom the early 1990s and may not re f l e c t c u rrent practices. Second, rapid on-site H b A 1 c m e a s u rements are used routinely in our practice and may play a role in impro ving glucose control (17). We may have been re f e rred and retained patients who are more motivated and there f o re achieve better results. Although our self-selected population cannot be compared directly with inclusive surveys such as NHANES III, our patients have a longer duration of diabetes than the NHANES III population (8), which makes our patients potentially more diff i c u l t to manage (3). We believe that good glycemic outcomes are attributable to a commitment to achieving normal metabolic status that is re i n f o rced through multiple contacts, including not only physician appointments but also nurse practitioner visits, dietitian visits, and telephone calls.
BP levels in our patients averaged 133/72 mmHg, which may reflect diff iculty in regulating systolic BP in a popula- 
